SESAME: Scientific Progress and Diplomacy


Eliezer Rabinovici, professor of Particle Physics at The Hebrew University of Jerusalem, recently received the 2019 Award for Science Diplomacy from the American Association for the Advancement of Science (AAAS) for his outstanding scientific and diplomatic contributions to SESAME (Synchrotron-light Experimental Science and Applications in the Middle East), founded in Jordan in 2017.

Read more

SESAME: Scientific Progress and Diplomacy


Eliezer Rabinovici, professor of Particle Physics at The Hebrew University of Jerusalem, recently received the 2019 Award for Science Diplomacy from the American Association for the Advancement of Science (AAAS) for his outstanding scientific and diplomatic contributions to SESAME (Synchrotron-light Experimental Science and Applications in the Middle East), founded in Jordan in 2017.

Read more

SESAME: Scientific Progress and Diplomacy


Eliezer Rabinovici, professor of Particle Physics at The Hebrew University of Jerusalem, recently received the 2019 Award for Science Diplomacy from the American Association for the Advancement of Science (AAAS) for his outstanding scientific and diplomatic contributions to SESAME (Synchrotron-light Experimental Science and Applications in the Middle East), founded in Jordan in 2017.

Read more

Breaking Down Resistance: Promising Brain Tumor Treatment


Professor Rotem Karni, of Hebrew University’s Institute for Medical Research-Israel-Canada, has designed a molecule that inhibits brain (glioblastoma) tumor growth by regulating the tumor-produced proteins.

Glioblastoma is a serious and incurable brain cancer. Until now, a patient diagnosed with glioblastoma typically has 11-20 months to live, and cells affected by this cancer quickly become resistant to chemotherapy treatment.

Read more

Breaking Down Resistance: Promising Brain Tumor Treatment


Professor Rotem Karni, of Hebrew University’s Institute for Medical Research-Israel-Canada, has designed a molecule that inhibits brain (glioblastoma) tumor growth by regulating the tumor-produced proteins.

Glioblastoma is a serious and incurable brain cancer. Until now, a patient diagnosed with glioblastoma typically has 11-20 months to live, and cells affected by this cancer quickly become resistant to chemotherapy treatment.

Read more

Something in the Air: Serious Underestimation of Global Warming


EMET Prize-winning scientist, Professor Daniel Rosenfeld, of Hebrew University of Jerusalem’s Herrmann Institute of Earth Sciences, has developed a satellite imaging method which has determined that the extent of global warming has been grossly underestimated.

Read more

Artificial Intelligence Algorithms Prove Pivotal to Quantum Physics


Professor Amnon Shashua from the Hebrew University of Jerusalem’s Rachel and Selim Benin School of Computer Science and Engineering has succeeded in proving mathematically that methods leading the field of artificial intelligence (the same as those that gave us voice and facial recognition abilities) can help to understand phenomena in quantum physics.

Read more

Artificial Intelligence Algorithms Prove Pivotal to Quantum Physics


Professor Amnon Shashua from the Hebrew University of Jerusalem’s Rachel and Selim Benin School of Computer Science and Engineering has succeeded in proving mathematically that methods leading the field of artificial intelligence (the same as those that gave us voice and facial recognition abilities) can help to understand phenomena in quantum physics.

Read more

Discovery of Promising Cure for Day Blindness by Gene Therapy


Prof. Ron Ofri of Hebrew University of Jerusalem’s Koret School of Veterinary Medicine has developed a gene therapy that may cure hereditary day blindness, called achromatopsia. People affected by this vision disorder cannot see in bright daylight, can only see in low-light conditions, and have low visual acuity and colorblindness as well.

Read more

Discovery of Promising Cure for Day Blindness by Gene Therapy


Prof. Ron Ofri of Hebrew University of Jerusalem’s Koret School of Veterinary Medicine has developed a gene therapy that may cure hereditary day blindness, called achromatopsia. People affected by this vision disorder cannot see in bright daylight, can only see in low-light conditions, and have low visual acuity and colorblindness as well.

Read more